Close Menu

NEW YORK (360Dx) – VolitionRx announced today that it has signed agreements with academic partners to conduct large-scale clinical studies of its Nu.Q colorectal cancer screening platform in the Asia Pacific region.

The Nu.Q platform is based on the company's Nucleosomics technology for identifying and quantifying nucleosome structural features such as histone modifications and variations, DNA methylation patterns, and nucleosome-protein adducts.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.